PulseAugur
EN
LIVE 15:29:16

Mammogen to launch $500 RNA blood test for breast cancer detection

By PulseAugur Editorial · [1 sources] ·

Mammogen is developing a $500 RNA blood test aimed at detecting breast cancer in women with dense breasts. CEO Elizabeth Cormier-May plans to offer the test directly to consumers, supported by a Series A funding round led by a pension fund and a trial involving 2,600 women. AI

RANK_REASON The item describes a new consumer-facing medical test, which falls under the 'tool' category as it's a product rather than a core AI development or significant industry shift.

Read on Forbes — Innovation →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Mammogen to launch $500 RNA blood test for breast cancer detection

How we ranked this

Signal score
2 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
The item describes a new consumer-facing medical test, which falls under the 'tool' category as it's a product rather than a core AI development or significant industry shift.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, funding
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
Breaking (< 6h)
Fresh story with cross-source coverage still developing. Ranking may shift as more sources report.

Full methodology in our editorial standards.

COVERAGE [1]

  1. Forbes — Innovation TIER_1 English(EN) · Geri Stengel, Contributor ·

    Mammogen Bets Women Will Pay $500 For A Breast Cancer Blood Test

    Mammogen CEO Elizabeth Cormier-May plans to sell a $500 RNA blood test directly to women with dense breasts, backed by a pension-led Series A and a 2,600-woman trial.

RELATED ENTITIES

RELATED TOPICS